Should I buy or sell LumiraDx stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LMDX shares. View LMDX analyst ratings or view top-rated stocks .

What is LumiraDx's stock price target for 2024?

1 Wall Street analysts have issued 1 year target prices for LumiraDx's shares. Their LMDX share price targets range from $0.80 to $2.70. On average, they expect the company's stock price to reach $1.75 in the next year. View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts .

How were LumiraDx's earnings last quarter?

LumiraDx Limited (NASDAQ:LMDX) posted its quarterly earnings data on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $21.07 million. During the same period in the previous year, the firm earned ($0.58) earnings per share.

NASDAQ:LMDX

LumiraDx (LMDX) Stock Price, News & Analysis

→ Chances are you know the firms on this list (From WealthPress) (Ad)

Free LMDX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: N/A
50-Day Range: $0.0076
▼
$0.0160
52-Week Range: N/A

Volume: 132.24 million shs
Average Volume: 56.75 million shs
Market Capitalization: $5.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.75

Stock Analysis Analyst Forecasts Earnings Headlines Ownership Short Interest Social Media

Get LumiraDx alerts:

Ad DTI

Start loving Mondays like this

Wouldn’t you love to start looking forward to Mondays? We’re in a New Paradigm Shift in the market that could make it possible! You see, rallies over the weekends have become much more common in the last few years. Imagine hitting a few buttons on your phone or laptop to place a quick trade before the weekend hits… And coming back on Monday to what could be extra income sitting in your account… Weekend after weekend!

Weekend after weekend!

About LumiraDx Stock (NASDAQ:LMDX)

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Ad DTI

Start loving Mondays like this

Weekend after weekend!

LMDX Stock News Headlines

April 14, 2024 | morningstar.com

LumiraDx Ltd LMDXF

January 31, 2024 | reuters.com

LMDX.O

April 20, 2024 | TradingTips (Ad)

3 Sub-$10 Stocks to Buy for 2024

Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.

January 8, 2024 | msn.com

Why LumiraDx Shares Are Trading Lower By Over 30%; Here Are 20 Stocks Moving Premarket

January 8, 2024 | investorplace.com

Why Is LumiraDx (LMDX) Stock Down 13% Today?

January 5, 2024 | finance.yahoo.com

LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th

January 2, 2024 | msn.com

Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology

January 2, 2024 | benzinga.com

Roche Agrees To Purchase Part Of COVID-19 Test Player LumiraDx Diagnostics Platform For $295M

April 20, 2024 | Tips4Traders (Ad)

Uncover this 2024 Hidden Gem

Exclusive Report: Uncover a Hidden Investment Gem We’re excited to share a special report on one exceptional, publicly traded company. This company has achieved a remarkable 22+% just this year, outperforming the market and revealing the potential for significant gains.

January 2, 2024 | benzinga.com

Why LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket

January 2, 2024 | msn.com

LumiraDx falls on agreement with Roche to sell assets

December 29, 2023 | reuters.com

Roche to buy part of LumiraDx diagnostics platform for $295 million

December 29, 2023 | finanznachrichten.de

LumiraDx Inc: LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

December 29, 2023 | finance.yahoo.com

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

December 29, 2023 | markets.businessinsider.com

LumiraDx Agrees To Sell Point-of-Care Tech Platform To Roche

December 29, 2023 | finance.yahoo.com

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

December 29, 2023 | finance.yahoo.com

LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche

December 26, 2023 | uk.finance.yahoo.com

LumiraDx Limited (LMDX)

November 27, 2023 | msn.com

LumiraDx (LMDX) Price Target Increased by 12.50% to 1.22

November 15, 2023 | morningstar.com

LumiraDx Ltd LMDX

November 2, 2023 | benzinga.com

Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

October 31, 2023 | benzinga.com

Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

October 28, 2023 | finanznachrichten.de

LumiraDx Inc: LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

October 27, 2023 | finance.yahoo.com

LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal

October 24, 2023 | msn.com

Why Is LumiraDx (LMDX) Stock Down 35% Today?

October 20, 2023 | finanznachrichten.de

LumiraDx Inc: LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England's First Heart & Lung Screening Hub

September 27, 2023 | finance.yahoo.com

LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

See More Headlines

Receive LMDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LumiraDx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/24/2023
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:LMDX
CUSIP: N/A
CIK: 1685428
Web: www.lumiradx.com
Phone: 354-640-0540
Fax: N/A
Employees: 1,210
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.75
High Stock Price Target: $2.70
Low Stock Price Target: $0.80
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-447,790,000.00
Net Margins: -268.45%
Pretax Margin: -264.58%
Return on Equity: N/A
Return on Assets: -77.91%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.45
Quick Ratio: 0.23

Sales & Book Value

Annual Sales: $126.52 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.33) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 318,546,000
Free Float: 205,749,000
Market Cap: $5.10 million
Optionable: Not Optionable
Beta: 1.73

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Ms. Veronique Ameye EMBA (Age 46)
Esq., M.B.A., CEO & General Counsel
Mr. Dorian LeBlanc CPA (Age 48)
CFO & VP of Global Operations
Ms. Colleen McMillen
Vice President of Communications
Andy Ward
National Sales Director - UK
Mr. David Walton DMS (Age 69)
Chief Commercial Officer
Giffin Daughtridge
President of North America Commercial Operations & Global Molecular Solutions
Melissa Garcia
VP & Corporate Counsel

Key Competitors

View All Competitors

Institutional Ownership

Senvest Management LLC
Sold 2,522,037 shares on 2/12/2024
Ownership: 2.534%

View All Institutional Transactions

LMDX Stock Analysis - Frequently Asked Questions

Should I buy or sell LumiraDx stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for LumiraDx in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LMDX shares.
View LMDX analyst ratings or view top-rated stocks.
What is LumiraDx's stock price target for 2024?: 1 Wall Street analysts have issued 1 year target prices for LumiraDx's shares. Their LMDX share price targets range from $0.80 to $2.70. On average, they expect the company's stock price to reach $1.75 in the next year.
View analysts price targets for LMDX or view top-rated stocks among Wall Street analysts.
How were LumiraDx's earnings last quarter?: LumiraDx Limited (NASDAQ:LMDX) posted its quarterly earnings data on Thursday, August, 24th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.01. The firm had revenue of $21 million for the quarter, compared to the consensus estimate of $21.07 million. During the same period in the previous year, the firm earned ($0.58) earnings per share.

This page (NASDAQ:LMDX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

LumiraDx (LMDX) Stock Price, News & Analysis

About LumiraDx Stock (NASDAQ:LMDX)

LMDX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

LMDX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info